Introduction: mTOR signalling pathway has emerged as a promising target for well-differentiated endocrine pancreatic carcinoma therapy. Because of varying behavior, INT are usually excluded from clinical trials employing the mTOR inhibitor, RAD001.
Aim(s): We conducted a retrospective analysis of incidence of INT in a mono-institutional series revised with WHO classification and validated with immunohistochemestry (IHC) for general and specific endocrine markers.
Materials and methods: Thirty-one carcinoid tumors were analyzed with follow-up between 1984 and 2007. All patients had G1 tumors with stage IV for synchronous liver metastases. Twenty-five out of 31 patients underwent primary surgery. IHC evaluation of the phosphorilated mTor was carried out in 19 primary tumors (T) and 19 liver metastases (M). The staining for pmTOR was optimised employing slides of normal kidney as positive control.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Massimo Milione
, Pusceddu S
, Buzzoni R
, Damato A
, Coppa J
, Pellegrinelli A
, Dominoni F
, Scuro M
, De Braud F
, Mazzaferro V
, Pelosi G
To read results and conclusion, please login ...
Further abstracts you may be interested in